Zoonotic & Vector-Borne Diseases

The agency says additional time is needed to decide upon a phase 4 program.

With recent reports of this vector-borne illness in the continental United States, there is concern this might become endemic in the country again.

The vaccine is steps behind another Chikungunya vaccine candidate from Valneva, which is currently under priority review by the FDA.

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?

Find out why the FDA requested additional data and what this means for dengue prevention.

6 malaria cases were confirmed in Florida and 1 in Texas, with no connection to international travel.

The federal agency has identified a total of 5 cases in Florida and Texas within the last two months.

The vaccine induced seroprotective chikungunya virus neutralizing antibodies in 98.9% of participants, regardless of age, and levels were maintained for up to 180 days.

This model proposes a risk threshold for recommending rabies postexposure prophylaxis (PEP), potentially reducing unnecessary treatments and associated costs.

The Gates Medical Research Institute (MRI) is collaborating with Atreca on an investigational therapy, MAM01, which is moving into clinic trials this year.

Among mpox patients treated with tecovirimat, there was no difference in treatment outcomes between those living with HIV and those without HIV.

The floods, heat waves, droughts, and other calamities caused by excessive greenhouse gas emissions also make us more vulnerable to ill effects of pathogens such as bacteria, viruses, plants and fungi.

The R21/Matrix-M vaccine can now be used in Ghana and could help in the prevention of a vector-borne disease that kills over 600,000 people annually.

The case and another probable case is being presented at next week’s European Congress of Clinical Microbiology & Infectious Diseases conference.

This week's hottest topics included the risks of proton pump inhibitors, rare tickborne disease, HIV vaccination, COVID-19 immunity from a common cold, and hydrocortisone for pneumonia.

The incidence rate of babesiosis in Maine, Vermont, and New Hampshire saw a dramatic increase over a multiyear period and saw an increase overall in other states where the disease is endemic.

New York City has ended their mpox outbreak after months of successful community outreach and vaccination campaigns.

This first-in-human, phase 1 vaccine trial produced a lasting immune response against Marburg virus.

These diseases, exacerbated by poor water quality, sanitation, and health care access, are highlighted today.

Rapidly distributing vaccines to at least 1/3 of at-risk populations, in addition to increasing tasting and contact tracing, may adequately stop the spread of mpox.

With limited health care infrastructure and large swaths of remote areas, developing countries face difficulties in medical management with these viruses and parasitic diseases.

Hong Kong confirmed a case of a man critically ill with avian influenza. On the other side of the world, Colorado is reporting its worst-ever avian flu outbreak among birds of prey.

The VIASURE PCR diagnostic is now available under Emergency Use Authorization in laboratories for persons with a suspected mpox infection.

This unusual Case Study describes a young woman who presented with an acute onset of headaches and dizziness and was found to have aseptic meningitis.

TP-05, a novel, oral therapeutic recently reported topline results from its phase 1 study.

A single-dose of acoziborole could simplify the treatment of this fatal infection.

As someone who lives with the long-term effects of chikungunya, Camillo Mora PhD, sees the expanding habitat of mosquitos and is concerned more people will be exposed to vector-borne illnesses and deal with not only the acute phases of these viruses but also the possibility of long-term health effects they can present.

The European Commission has approved their first dengue vaccine, Takeda’s TAK-003, as climate change and urbanization contribute to a worldwide rise in dengue incidence.

The investigational shot from Pfizer and Valneva demonstrated higher antibody levels in the three-dose vaccination schedule versus the two-dose vaccination schedule.

Takeda’s investigational dengue vaccine TAK-003 is currently under evaluation for preventing any dengue virus serotype in individuals 4-60 years old.